AstraZeneca plc (LON:AZN) has been given a GBX 4,200 ($54.72) price objective by investment analysts at J P Morgan Chase & Co in a research note issued to investors on Friday. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. J P Morgan Chase & Co’s target price indicates a potential downside of 2.89% from the stock’s previous close.
Other equities analysts have also issued reports about the company. BNP Paribas reaffirmed a “neutral” rating and set a GBX 5,300 ($69.05) price target on shares of AstraZeneca plc in a research note on Monday, April 3rd. UBS AG set a GBX 5,150 ($67.09) price target on AstraZeneca plc and gave the company a “neutral” rating in a research note on Wednesday, April 5th. HSBC Holdings plc reaffirmed a “reduce” rating and set a GBX 4,200 ($54.72) price target on shares of AstraZeneca plc in a research note on Friday, May 5th. Shore Capital reaffirmed a “sell” rating on shares of AstraZeneca plc in a research note on Wednesday, May 10th. Finally, Berenberg Bank increased their price target on AstraZeneca plc from GBX 5,670 ($73.87) to GBX 5,850 ($76.21) and gave the company a “buy” rating in a research note on Wednesday, May 17th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and nine have given a buy rating to the company. The stock has an average rating of “Hold” and an average price target of GBX 5,189.30 ($67.60).
Shares of AstraZeneca plc (LON AZN) opened at 4415.00 on Friday. The firm’s market cap is GBX 55.89 billion. The firm has a 50-day moving average price of GBX 5,187.89 and a 200-day moving average price of GBX 4,861.95. AstraZeneca plc has a 52-week low of GBX 3,996.00 and a 52-week high of GBX 5,520.00.
TRADEMARK VIOLATION WARNING: “AstraZeneca plc (LON:AZN) PT Set at GBX 4,200 by J P Morgan Chase & Co” was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://stocknewstimes.com/2017/07/28/astrazeneca-plc-lonazn-pt-set-at-gbx-4200-by-j-p-morgan-chase-co.html.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.
